TheEdgeResearch
Home / Stocks / GKOS

Glaukos Corporation (GKOS)

NYSE Healthcare Medical - Devices
$161.66 ▲ +6.83%
Market Cap
$9.49B
Sector
Healthcare
Industry
Medical - Devices
Beta
0.75
52-Wk Range
73.16-166
CEO
Thomas William Burns
Country
US
Currency
USD

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as we…

Open full interactive analysis & DCF →